For the roughly one in three adults with both type 2 diabetes and chronic kidney disease who struggle to reach blood pressure targets, the therapeutic ceiling has long felt frustratingly low. A secondary analysis of the CONFIDENCE trial now offers a mechanistically coherent reason to reconsider combination therapy as a default rather than a fallback.
The analysis drew on 800 participants stratified by baseline systolic blood pressure (SBP) — 66% entered with SBP at or above 130 mm Hg. Combining finerenone, a nonsteroidal mineralocorticoid receptor antagonist, with the SGLT2 inhibitor empagliflozin nearly doubled the odds of achieving a clinically meaningful SBP reduction of 10 mm Hg or more compared with finerenone monotherapy (OR 1.83; 95% CI 1.21–2.76), with a directionally consistent but less decisive advantage over empagliflozin alone (OR 1.45; 95% CI 0.97–2.17). Baseline SBP emerged as the dominant predictor of response — each 10 mm Hg increment at enrollment was associated with a twofold increase in response odds. Critically, causal mediation analysis suggested that early SBP reductions at day 30 partially explain the albumin-to-creatinine ratio improvements seen at day 180, implying blood pressure control may be a meaningful mechanistic pathway — not merely a parallel benefit.
This is a secondary, exploratory analysis of a trial not primarily powered for blood pressure endpoints, which limits causal inference. That said, the biological plausibility is strong: finerenone blocks aldosterone-driven sodium retention and fibrosis, while empagliflozin induces osmotic diuresis through glucosuria — complementary, non-overlapping pressure-lowering mechanisms. The finding that combination therapy appears safe without excess hypotension addresses a clinically important concern. For a cardiorenal population already at high risk, this incremental evidence — though not definitive — positions the combo as worthy of prospective trials with SBP as a primary endpoint. Confirmatory Phase III data remain the necessary next step before guideline uptake.